Board of Directors
Learn about our Board of Directors and the experience that they bring to Hemanext.
President and CEO - Hemanext
Former Senior Partner at Monitor Deloitte
Guy Cogan is a Senior Partner at Monitor Deloitte and serves as the Global Leader for Strategy and Operations Consulting. Guy started his career at Bain & Company in London, England where he ultimately served as the Managing Partner of the UK operations. He has also held leadership positions at AT Kearney and Monitor Group, before its acquisition by Deloitte Consulting. With 30 years of industry and consulting experience, his work has included both accelerating growth and improving profitability at corporate and business unit levels for major global clients. Guy holds a BA and MA in Engineering from St Catharine’s College, Cambridge University, as well as an MBA from the Harvard Business School, where he was named a Baker Scholar.
Classic Communities Organization CEO
American Enterprise Institute Resident Fellow
Former Vice Chairman and Chief Investment Officer, T. Rowe Price
Director and Owner of Empresas Indumotora SA
Former partner in the corporate finance and M&A practice of Latham & Watkins LLP
Paul M. Ness, M.D.
Senior Director of the Transfusion Medicine Division and Professor of Pathology, Medicine, and Oncology at the Johns Hopkins University School of Medicine
Dr. Ness served as Division Director from 1979-2018. From 1983-2000 he directed the Baltimore division of American Red Cross Blood Services leading the Baltimore community through the transfusion issues with the AIDS epidemic. At Johns Hopkins he helped to develop programs in patient blood management, bloodless medicine, therapeutic apheresis, and advanced immunohematology. Prior to coming to Hopkins, he was an undergraduate at MIT, a medical student at SUNY Buffalo, a medical resident at Hopkins, a staff associate in the blood program at NIH, and a hematology –transfusion medicine fellow at UC San Francisco
Dr. Ness was a member of the AABB Board of Directors for many years and became President in 1999. He served as editor of Transfusion from 2003-2018. Dr. Ness has written over 250 articles for medical journals and three texts. Dr. Ness also has extensive experience in transfusion related research with emphasis upon transfusion complications including transfusion transmitted infections and immune destruction of transfused cells. He was a member of the FDA Blood Products Advisory Committee and is currently a member of the Health and Human Services Advisory Committee of Blood and Tissue Safety and Availability.
He served as PI for the Johns Hopkins site of the Transfusion Medicine Hemostasis Clinical Trial Network, funded by NHLBI. Dr. Ness was co-PI for a project funded by the NHLBI REDS III program to study donor virus epidemiology and blood utilization issues in China. He has served as a consultant to the coordinating centers of REDS II, REDS III, and REDS IV. He continues to serve as a consultant to many companies involved in transfusion medicine supplies and practices.